Panbela Therapeutics, Inc. (PBLA) Research

Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.

Market snapshot

Symbol
PBLA
Price
$0.01
Day change
0.00%
Market cap
$53.9K
P/E ratio
-0.00x
52-week range
0.0001-2.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Advantis Corp. (ADVT)
  • Black Bird Biotech, Inc. (BBBT)
  • Braxia Scientific Corp. (BRAXF)
  • Ehouse Global, Inc. (EHOS)
  • Hard to Treat Diseases Inc. (HTDS)
  • IR Biosciences Holdings Inc. (IRBS)
  • Mobile Lads Corp. (MOBO)
  • Novo Integrated Sciences, Inc. (NVOS)

Recent insider activity

  • Nant Capital, LLC — P-Purchase (0 shares) on 2024-11-15
  • Nant Capital, LLC — trade (7702702 shares) on 2024-10-22
  • Horvath Susan — A-Award (25480 shares) on 2024-10-01
  • Simpson Jennifer K. — A-Award (72800 shares) on 2024-10-01
  • GOLDMAN SACHS GROUP INC — S-Sale (72874 shares) on 2023-11-08

Open Panbela Therapeutics, Inc. (PBLA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.